Type 2 diabetes is typically a progressive condition where therapy advancement will normally be required for the patient to reaching glycemic targets. Although all guidelines recommend therapy advancement to reach glycemic targets, there is commonly inertia to add additional agents. Some of the reason for this inertia is likely due to the significant advances in therapy recommendations for people with type 2 diabetes. This allows for treatment that focuses beyond glycemic control, and the selection of agents that reduce the burden of diabetic complications. In this webinar, we will hear from international experts providing guidance on the individualization of therapy in patients with type 2 diabetes to improve glycemic control and reduce complication risk.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.